GHRH analogue
A modified growth-hormone-releasing hormone analogue, often discussed alongside other secretagogues.
Early human pharmacology studies show it can raise growth-hormone and IGF-1 levels, but there is little robust trial evidence for the longevity or body-composition claims commonly attached to it.
Unapproved injectable supply means uncertain purity and dosing. Reported effects include water retention, flushing and headaches; long-term safety in healthy people is not established. Prohibited in sport.
Not ARTG-approved as a finished medicine. Online "research" supply is not a lawful pathway for human use.
No general lawful supply for human use. It may be discussed in a compounding context under prescription, but it is not ARTG-registered and online supply is unregulated.
Both are GHRH analogues, but they are different molecules with different regulatory status: sermorelin has a prescription pathway, whereas CJC-1295 is not ARTG-approved.
This entry is general information about CJC-1295, not a recommendation to use it. We don’t provide dosing, protocols or sourcing. Speak to a registered practitioner.
This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.